ArticleBlood2022
CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network.
Open access · bronzeAbstract readLetter
In one paragraph
Article in Blood, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 4 pooled it
4.7field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 4 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Role of rituximab in treatment of patients with primary central nervous system lymphoma: An updated systematic review and meta-analysis.Acta neurologica Belgica · 2026Pooled it
- Safety and efficacy of CAR T-cell therapy in central nervous system lymphoma: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Efficacy and safety of chimeric antigen receptor T-cells treatment in central nervous system lymphoma: a PRISMA-compliant single-arm meta-analysis.Cancer immunology, immunotherapy : CII · 2023Pooled it
- Pooled it
- Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial.Blood · 2022Trial
- Review
- Genetic orchestration of the primary central nervous system lymphoma microenvironment.Biomarker research · 2026Review
- Breakthroughs and challenges of CAR-T cell therapy in treating hematologic malignancies of the central nervous system.Blood science (Baltimore, Md.) · 2026Review
- Mapping the immune orchestra of zamtocabtagene autoleucel in primary CNS lymphoma.Haematologica · 2026Article
- Patterns, risk factors and management of CD19-directed chimeric antigen receptor T-cell therapy failure in CNS lymphoma.Journal of hematology & oncology · 2026Article
- Advances in CAR-T therapy for central nervous system lymphoma.Frontiers in immunology · 2026Review
- Novel Agents and Immunotherapies for Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System: Innovating for Impact in a Disease With Unmet Needs.Journal of hematology · 2025Review
- Outcomes of CD19 CAR-T therapy in central nervous system lymphoma: Insights from a multicentre experience.British journal of haematology · 2025Article
- Preliminary evidence of CAR T-cell therapy activity in vitreoretinal lymphomas: An LOC network study.HemaSphere · 2025Article
- Simultaneous determination of 7 thiols associated proteins in lymphoma patients'serum and cerebrospinal fluid by UHPLC-HRMS technique.Scientific reports · 2025Article
- BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement.Blood advances · 2025Article
- Anti-CD19 CAR T-cell therapy for primary and secondary CNS lymphomas.Bone marrow transplantation · 2025Review
- Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy.Haematologica · 2025Article
- The contemporary spectrum of radiotherapy for hematologic malignancies involving the central nervous system: From focal therapy to craniospinal.Seminars in radiation oncology · 2025Review
- CAR-T Cells for the Treatment of Central Nervous System Tumours: Known and Emerging Neurotoxicities.Brain sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 5 institutions in 1 country.
Marion AlcantaraCenter for Cancer Immunotherapy, INSERM Unité 932, Institut Curie, PSL Research University, Paris, France.ORCID 0000-0002-2912-0343
Caroline HouillierService de Neurologie 2-Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP) Sorbonne Université, Instituts Hospitalo-Universitaires (IHU)Institut du Cerveau (ICM), Paris, France.
Marie BlonskiService de Neurologie, Centre Hospitalier Régional Universitaire (CHRU), Nancy, France.
Marie-Thérèse RubioDepartment of Hematology, Brabois Hospital, Centre Hospitalier Régional Universitaire, Nancy, France.
Lise WillemsClinical Hematology Unit, Hôpital Cochin, AP-HP, Paris, France.
Agathe Waultier RascalouClinical Hematology Unit, Centre Hospitalier Universitaire de Nîmes, Nîmes, France.
Magali Le Garff-TavernierDepartment of Biological Hematology, Groupe Hospitalier Pitié-Salpêtrière, AP-HP Sorbonne Université, Paris, France.ORCID 0000-0002-3131-3240
Karim MaloumDepartment of Biological Hematology, Groupe Hospitalier Pitié-Salpêtrière, AP-HP Sorbonne Université, Paris, France.ORCID 0000-0001-8864-4801
Clotilde BravettiDepartment of Biological Hematology, Groupe Hospitalier Pitié-Salpêtrière, AP-HP Sorbonne Université, Paris, France.
Laetitia SouchetClinical Hematology Unit, Groupe Hospitalier Pitié-Salpêtrière, AP-HP Sorbonne Université, Paris, France.
Damien Roos-WeilClinical Hematology Unit, Groupe Hospitalier Pitié-Salpêtrière, AP-HP Sorbonne Université, Paris, France.ORCID 0000-0002-7767-755X
Véronique MorelClinical Hematology Unit, Groupe Hospitalier Pitié-Salpêtrière, AP-HP Sorbonne Université, Paris, France.
Madalina UzunovClinical Hematology Unit, Groupe Hospitalier Pitié-Salpêtrière, AP-HP Sorbonne Université, Paris, France.
Carole MetzUnité REQPHARM, Pharmacie à Usage Intérieur, Groupe Hospitalier Pitié-Salpêtrière, AP-HP, Paris, France.
Meriem Dhib-CharfiUnité REQPHARM, Pharmacie à Usage Intérieur, Groupe Hospitalier Pitié-Salpêtrière, AP-HP, Paris, France.
Stéphanie NguyenClinical Hematology Unit, Groupe Hospitalier Pitié-Salpêtrière, AP-HP Sorbonne Université, Paris, France.
Natalia ShorService de Neuro-Radiologie, Groupe Hospitalier Pitié-Salpêtrière, AP-HP, Paris, France; and.ORCID 0000-0003-0693-1829
Dimitri PsimarasService de Neurologie 2-Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP) Sorbonne Université, Instituts Hospitalo-Universitaires (IHU)Institut du Cerveau (ICM), Paris, France.
Nicolas WeissUnité de Médecine Intensive Réanimation Neurologique, Département de Neurologie, DMU Neurosciences et Institut de Neurosciences Translationnelles, AP-HP Sorbonne Université, IHU, ICM Groupe Hospitalier Pitié-Salpêtrière, Paris, France.ORCID 0000-0001-5155-196X
Nathalie JacqueClinical Hematology Unit, Groupe Hospitalier Pitié-Salpêtrière, AP-HP Sorbonne Université, Paris, France.
Silvia SolorzanoClinical Hematology Unit, Groupe Hospitalier Pitié-Salpêtrière, AP-HP Sorbonne Université, Paris, France.
Nicolas GauthierClinical Hematology Unit, Groupe Hospitalier Pitié-Salpêtrière, AP-HP Sorbonne Université, Paris, France.ORCID 0000-0001-5217-2769
Marie Le CannClinical Hematology Unit, Groupe Hospitalier Pitié-Salpêtrière, AP-HP Sorbonne Université, Paris, France.
Françoise NorolClinical Hematology Unit, Groupe Hospitalier Pitié-Salpêtrière, AP-HP Sorbonne Université, Paris, France.
Carole SoussainCenter for Cancer Immunotherapy, INSERM Unité 932, Institut Curie, PSL Research University, Paris, France.
Sylvain ChoquetClinical Hematology Unit, Groupe Hospitalier Pitié-Salpêtrière, AP-HP Sorbonne Université, Paris, France.
Sorbonne Université · FRCentre Hospitalier Régional et Universitaire de Nancy · FRInserm · FRCentre Hospitalier Universitaire de Nîmes · FRHôpital Cochin · FR
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Immunotherapy, AdoptiveAgedCentral Nervous SystemCentral Nervous System NeoplasmsCohort StudiesFemaleFranceHumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedSurvival Analysis
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.